Stocktoria
EXOZYMES INC. EXOZ
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2024-11-13
EXOZYMES INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | — | — | $70,069 |
| R&D expense | $3.7M | $1.9M | $527,480 |
| Operating income | -$9.7M | -$5.9M | -$1.8M |
| Income tax | -$105,205 | — | $42,267 |
| Net income | -$9.2M | -$5.9M | -$2.0M |
| EPS (diluted) | $-1.09 | $-0.89 | $-0.33 |
| Operating cash flow | -$6.5M | -$8.5M | -$1.2M |
| Free cash flow | -$6.7M | -$8.9M | -$1.5M |
| Cash & equivalents | $3.0M | $9.7M | $66,533 |
| Total assets | $6.0M | $13.0M | $3.6M |
| Total liabilities | $2.6M | $2.6M | $3.9M |
| Shareholders' equity | $3.4M | $10.4M | -$384,319 |
Source: SEC EDGAR filings · CIK 0002010788 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.